Invisible Ink

In this episode of Invisible Ink, Peter Walker, Head of Insights at Carta, joins Shubha Chakravarthy to cut through startup hype with real data from 60,000 startups and 3,000 venture funds. Peter is one of the most sought after data experts in the world of startups, and his posts and reports on the latest startup data are widely anticipated and read.In this episode, Peter shares his thoughtful, data-driven take on:Why venture capital became the default path for founders and why the data says that assumption is quietly breaking downThe single cap table decision made at incorporation that can make a company effectively unfundable years laterWhy academic and deep tech founders systematically misjudge equity tradeoffs and the early signal investors notice immediatelyThe uncomfortable truth about advisor equity and how well intentioned generosity quietly hollows out founder ownershipWhat Carta’s data reveals about how much equity actually matters and where founders obsess over the wrong numbersWhy SAFEs feel founder friendly early and how they quietly reshape ownership when it is too late to undoThe cap table red flags investors rarely say out loud but almost always noticeWhy most startup employees never make money on their equity even when the company does wellThe counterintuitive metric that matters more than revenue in the earliest days and how it aligns an entire companyWhy fundraising treated as a long slow conversation almost always fails and what disciplined founders do insteadThe myth of founders being pushed out by VCs and what actually determines who stays in controlThe hardest mindset shift founders must make to survive the journey long before outcomes exits or valuations are knownand much more!

In this episode of Invisible Ink, veteran operator Dr. Ron Weissman joins Shubha Chakravarthy to challenge some of the most entrenched myths in early-stage fundraising. Drawing on decades as a VC, angel investor, board member, and former NeXT executive who worked closely with Steve Jobs, Ron explains why startups fail. Key takeaways from the episode include:Why some founders immediately feel investable—even before the deck comes upThe question investors are really trying to answer in the first few minutesWhat years of looking at deals teaches investors that pitch contests never doWhy getting a fast yes from an investor can be more dangerous than a slow noThe part of diligence most founders don’t realize they’re being evaluated onWhat investors listen for when founders describe their market—not their productHow investors tell the difference between a strong pitch and a strong businessWhen a funding path helps you—and when it starts working against youThe moment investors decide whether they want to work with you long-termWhat a founder’s roadmap reveals that no slide ever says out loudHow deal structure shapes the relationship long before anything goes wrongThe shift in thinking investors expect from founders aiming to build category leaders and much more!

In this episode, Naseem Sayani, Director, Innovator's Circle, WHAM and VC investor & ecosystem builder, joins Shubha Chakravarthy to expose the structural gaps female founders face and how to overcome them with strategy, confidence, and financial clarity. Naseem breaks down why women often lead with pain instead of profit, why this undermines fundraising, and how shifting storytelling toward economic opportunity can transform investor outcomes. Drawing from deep experience in consulting, venture building, and women’s health innovation, she outlines the real reasons women negotiate less, accept predatory terms, and hesitate to take salaries—even when the business demands it.Check out Naseem's sharp insights on:Why most female founders lose investor interest early and the simple narrative shift that instantly changes the fundraising conversationThe hidden bias in “leading with pain” and how reframing your pitch around market size and money unlocks investor confidenceWhy founders routinely miscalculate market size and how to paint a compelling future vision that pulls investors toward your companyThe red flags investors look for in early teams and the specific “superpowers” founders must assemble from day oneThe most overlooked post-funding mistake women make and how to protect your equity and runway as you scaleWhy many founders underestimate predatory term sheet risks and how to build the small advisory circle that keeps you safeThe difference between a true product and a feature and the unforgiving test that reveals whether your idea is actually fundableWhy financial fluency matters more than financial perfection and how to speak to your model in ways that earn investor trustThe real reason founders stumble in regulated markets and how early clinical, payer, or regulatory expertise changes your trajectoryWhy leadership development determines whether you keep the CEO role and how coaching, community, and thought leadership help you scale with your company and much more!

Dan Gray, Head of Insights of Equidam, joins Shubha Chakravarthy to demystify one of the most misunderstood topics in early-stage fundraising—startup valuation. With over two decades in early-stage ventures, Dan reframes valuation not as a number but as a story that links a founder’s vision, strategy, and financial logic.Check out Dan's practical guidance for deep tech and non-consensus founders, and the systemic issues in venture capital that create hurdles for deep tech founders, and a smarter, story-driven approach to raising capital. Highlights include:Why founders must treat valuation as a story, not a number, and how the story drives belief and funding outcomesHow “SaaS bias” skews investor expectations and hurts deep tech founders raising their first roundThe single biggest fundraising mistake deep tech founders make,and how to fix it before it costs you equityHow to define milestones that de-risk your company and drive valuation up round after roundThe hidden logic behind dilution, and how to keep ownership while staying fundableWhat VCs really mean when they say “we don’t invest in hardware” (and how to turn that into an advantage)Why valuation models fail for science-based startups,and how to build credible DCF-driven stories investors believeThe investor’s portfolio math: how fund size, timing, and follow-on strategy affect your odds of getting fundedHow to spot “consensus capital” versus “non-consensus capital”, and why the difference could decide your futureThe truth about VC markups, management fees, and why exits don’t always drive investor behaviorThe “economic energy” test: how to articulate the total value your breakthrough can unlock for the worldThe one framing shift that turns founders from fund-seekers into informed customers of capitalHow to translate a visionary story into a credible financial model investors trustWhy financial literacy, not hype, is the real superpower for deep tech founders

In this episode of Invisible Ink, molecular biologist and biotech entrepreneur Daisy Robinton, founder of Oviva Therapeutics, joins Shubha Chakravarthy to share her journey from academia to leading a women’s health startup.Daisy turned a personal encounter with gaps in female physiology knowledge—despite holding a PhD— into her mission to address ovarian function as a key driver of women’s healthspan, all the way to a successful exit in a tough funding and M&A environment.Check out this episode for her thoughtful and pragmatic insights on:How to transition successfully from a scientist to founderHow to tell if your biotech asset is ready for commercializationHow to balance science and business as a scientist-founderThe challenges of fundraising in biotech and how to set yourself up for successThe art of making science-business tradeoffs, and how to do it wellHow to convince skeptical male investors of the market opportunity in women's healthTested tips from the trenches for first time CEO'sWhy storytelling is a game changer, and how to do it well for any audienceThinking ahead: exit and post-exit realitiesTips to leverage your scientific training to translate into any domainand much more!

In this episode of Invisible Ink, Dr. Maria Blehker—founder of Serendipity Capital and expert in behavioral science—joins Shubha Chakravarthy for a deep dive into how startups, particularly in deep tech and mental health, can succeed by blending scientific rigor with human insight and strategic funding.Check out this episode to hear her practical tips on how you can leverage research-driven insights from behavioral science to jumpstart progress with your startup as Maria shares her views on:Serendipity Impact VC's thesis and the market opportunity in mental healthThe emerging founder trends driving new healthcare startupsWhy behavioral science is your secret superpower to accelerate your startup's successHow to accelerate customer acceptance of your new product Simple steps to improve your sales success in selling an unproven product to a resistant marketThen one small reframe that can turn prospects from apathetic to enthusiasticHow to find critical flaws in your product without getting your soul crushedSmall but powerful ways to overcome stereotype bias that anyone can useSecrets to building strong investor relationships long before you need themand much more!

In this episode of Invisible Ink, Eileen Tanghal, Co-founder and Managing Partner at Black Opal Ventures, joins Shubha Chakravarthy for a deep dive into how founders can better understand venture capital beyond just fundraising and what truly drives VC decision-making.Eileen reveals what founders often miss: that VCs are entrepreneurs too, managing their own businesses with investor expectations and partnership dynamics. She outlines how founders should think more like CEOs—understanding venture returns, fund dynamics, and how their startup fits into the investor’s portfolio strategy. Tune in for Eileen's insights on: How VC fundable opportunities are bornHow to get on the same page with a VC instantlyThe three layers of VC decision making most founders don't knowWhat drives the decision: inescapable VC math it pays for you to knowHow VCs really evaluate your financial modelInside tips on what makes your roadmaps credible to a VCHow TAM, SAM SOM play into a VC's funding decisionWhat VC's look for when assessing your milestonesThe real test of whether you have a great team, as a VC sees itHow to demonstrate credibility even if you've never built a startup or raised funding beforeThree top takeaways you can implement tomorrowand much more!

In this episode, Ingrid Bonde Åkerlind joins Shubha Chakravarthy to unravel the complexities of pricing for early-stage startups, especially in the world of SaaS and “XaaS” business models.Tune in to hear Ingrid's reflections on her unexpected journey into pricing, starting from scratch in a C2C marketplace to making investment decisions with a venture capital firm. Ingrid shares powerful insights about price inertia, customer psychology, and how anchoring and framing play critical roles in both B2B and B2C contexts. Don't miss her practical and actionable insights on:Why pricing is often the orphan function in early-stage startups—and why it shouldn't be.The psychological biases that impact pricing—across both B2C and B2B markets.Why SaaS and XaaS pricing models are harder than they look.Key differences in pricing strategy for early-stage versus mature startups.How to use customer interviews for pricing research—even without hard data.Why pricing isn't just about the number, but about picking the right value metric.Best practices for testing different pricing models with early customers.Practical tips for reviewing and iterating on your pricing regularly.and much more!

In this episode, Maja Voje, go-to-market strategist, author, and growth expert, joins Shubha Chakravarthy to unpack the real essence of go-to-market (GTM) strategy—far beyond the buzzword.Drawing from her extensive experience advising startups and corporates alike, Maja reveals her tested GTM framework, rooted in experimentation, structured thinking, and real market insights. She breaks down the six mission-critical elements of GTM: understanding the market and competition, defining your early customer profile (ECP), building value-aligned products, crafting sharp positioning and messaging, pricing based on perceived value and evidence, and finally, setting up scalable growth and sales channels. Check out her information-packed, tested and foolproof views on:How to define and validate your go-to-market strategy early onWhy “launch” is not the same as go-to-market, and why that mattersHow to pick your beachhead market and early customer profile (ECP)How to think about your product in a way that improves the odds of product market fitWhat product-market fit actually looks like in the real worldWhy pricing isn’t just about numbers and what to focus on in setting priceHow to position your product to stand out (without overthinking it)How to choose and sequence your growth channelsThe top 3 actions for founders rethinking their GTM strategyand much more!

In this captivating episode, we sit down with Maria L. Maccecchini, a force of nature in the world of biotech, to explore her inspiring journey from a Ph.D. scientist to a successful entrepreneur. Maria shares her passion for developing innovative treatments for neurodegenerative diseases including Alzheimer's and Parkinson's, and the realities of navigating the complex terrain of funding, clinical trials, and FDA approvals.Check out her fascinating journey across two continents founding a successful startup, her journey to wealth, and her subsequent decision to plunge back into the world of entrepreneurship. Check out her fascinating insights on:How innovation works in pharma and why it matters to life sciences entrepreneursHow success and wealth play out in life sciences and what it means to foundersThe unexpected lessons from repeat entrepreneurship in life sciencesWhy VC funding is challenging to raise in life sciences startupsHow unexpected shocks from bad actors in the system can derail your startup, and how to tackle themThe nuts of bolts of getting FDA approval, and the factors that make it challengingWhy life sciences entrepreneurs decide to IPOThe challenges of being a public life sciences company CEO, and tips on handling the jobPersonal lessons from a lifetime of curiosity and play that anyone can follow. and much more!

In this episode, Patricia Liu, an MIT-educated computer scientist turned angel investor and Stanford lecturer, shares her diverse career journey—from consulting at Accenture to working in Michelin-starred kitchens and now teaching pitch decks to startup founders.Patricia shared her takes on the common threads across her careers, the core elements that stay constat regatdless of what endeavor you're engaged in. Check out her thoughtful and unique views on:How to set up your pitch so investors pay attention from the first slideThe one thing that makes your pitch unforgettable to investorsWhat the best pitches have in common, even when they describe complex technologies The one underrated activity that can make or break your funding chancesHow to build trust and keep investors hooked with this simple hackHow to really demonstrate a big and credible competitive edgeThe one thing that can kill your pitch—and how to avoid itSimple tools that can turn complex ideas into instant investor buy-inThe simple activity anyone can do to expose the weak spots you never noticedHow to make your deck stand out in a sea of forgettable pitchesand much more!

In this episode, Liz Sigety, chair of Fox Rothschild's Emerging Companies and Venture Capital practice, shares her expertise in working with startups, her role as a co-founder of the Delaware Crossing Investor Group, and her extensive experience as an angel investor.Tune in to hear Liz's thoughts on funding mechanisms for early-stage companies, how to pick the right funding vehicle, the differences between SAFEs and convertible notes, and what founderss should think about in selecting the right one for their raise.Get a deep dive on the Angel Capital Association's new Model Convertible Note straight from the source! Liz headed the team at the ACA that worked to develop and publish this comprehensive new template!Hear Liz's thoughts on: The critical factors that drive your choice of funding vehiclePrimary differences between SAFEs and convertible notesHow legal fees impact your choice of funding vehicle, and what ti keep in mindThe little known tax issue that can make or break your deal for investorsWhy tax matters for you as a founder, and how ti minimize your tax riskHow the ACA's new model convertible note changes the game for founders and investorsThe make or break features of your convertible note: discounts, valuation caps and maturityThe "iceberg" factors of convertible notes: early sale, board representation, information rights and moreHow to put together a foolproof term sheet as a first time founderInsider tips for women founders in STEM from an experienced angel and attorneyand much more.Only on Invisible Ink!